1. Home
  2. ETON vs CUB Comparison

ETON vs CUB Comparison

Compare ETON & CUB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETON
  • CUB
  • Stock Information
  • Founded
  • ETON 2017
  • CUB 2024
  • Country
  • ETON United States
  • CUB United States
  • Employees
  • ETON N/A
  • CUB N/A
  • Industry
  • ETON Biotechnology: Pharmaceutical Preparations
  • CUB
  • Sector
  • ETON Health Care
  • CUB
  • Exchange
  • ETON Nasdaq
  • CUB NYSE
  • Market Cap
  • ETON 329.8M
  • CUB 310.7M
  • IPO Year
  • ETON 2018
  • CUB 2024
  • Fundamental
  • Price
  • ETON $14.22
  • CUB $10.24
  • Analyst Decision
  • ETON Strong Buy
  • CUB
  • Analyst Count
  • ETON 3
  • CUB 0
  • Target Price
  • ETON $27.67
  • CUB N/A
  • AVG Volume (30 Days)
  • ETON 248.9K
  • CUB 28.2K
  • Earning Date
  • ETON 03-18-2025
  • CUB 01-01-0001
  • Dividend Yield
  • ETON N/A
  • CUB N/A
  • EPS Growth
  • ETON N/A
  • CUB N/A
  • EPS
  • ETON N/A
  • CUB N/A
  • Revenue
  • ETON $39,011,000.00
  • CUB N/A
  • Revenue This Year
  • ETON $107.69
  • CUB N/A
  • Revenue Next Year
  • ETON $65.50
  • CUB N/A
  • P/E Ratio
  • ETON N/A
  • CUB N/A
  • Revenue Growth
  • ETON 23.29
  • CUB N/A
  • 52 Week Low
  • ETON $3.03
  • CUB $9.96
  • 52 Week High
  • ETON $18.41
  • CUB $10.55
  • Technical
  • Relative Strength Index (RSI)
  • ETON 43.84
  • CUB N/A
  • Support Level
  • ETON $12.73
  • CUB N/A
  • Resistance Level
  • ETON $15.73
  • CUB N/A
  • Average True Range (ATR)
  • ETON 0.93
  • CUB 0.00
  • MACD
  • ETON -0.01
  • CUB 0.00
  • Stochastic Oscillator
  • ETON 49.67
  • CUB 0.00

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About CUB LIONHEART HOLDINGS

Lionheart Holdings is a blank check company.

Share on Social Networks: